{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:35:58Z","timestamp":1787243758454,"version":"build-2736575974"},"reference-count":48,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"unspecified","delay-in-days":26,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"publisher","award":["2023JJ70054"],"award-info":[{"award-number":["2023JJ70054"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Research Project of Health Commission of Hunan Province","award":["D202303069496"],"award-info":[{"award-number":["D202303069496"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82470910"],"award-info":[{"award-number":["82470910"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Diab Res Care"],"accepted":{"date-parts":[[2025,12,15]]},"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Current studies have shown that the asialoglycoprotein receptor 1 (ASGR1) is involved in glycolipid metabolism and is associated with systemic insulin resistance. This study aims to explore the correlation between serum soluble ASGR1 (sASGR1) levels and metabolic dysfunction-associated steatotic liver disease (MASLD) by assessing the relationship between sASGR1 concentrations and various biomarker levels.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The study included 148 patients diagnosed with MASLD from December 2021 to July 2024, and 98 control participants from the general population without MASLD. After collecting baseline clinical characteristics, ELISA kits were used to measure serum levels of sASGR1, fibroblast growth factor 21, and adiponectin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Compared with the control group, patients with MASLD had higher serum sASGR1 levels (p&lt;0.05). Spearman correlation analysis showed that serum sASGR1 levels were significantly positively correlated with lipid metabolism indicators (triglycerides, total cholesterol, low-density lipoprotein cholesterol), glucose metabolism indicators (fasting plasma glucose, fasting insulin, glycosylated hemoglobin, homeostasis model assessment for insulin resistance), inflammatory markers (tumor necrosis factor \u03b1), liver function, and liver fibrosis. indicators (alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma glutamyl transferase, procollagen type III, hyaluronic acid), and body mass index (p&lt;0.05), and were significantly negatively correlated with high-density lipoprotein cholesterol (p&lt;0.05). Further multiple linear regression analysis showed sASGR1 may be an independent risk factor for the occurrence of MASLD after adjusting for potential confounding factors (OR 2.644, 95%\u2009CI 1.138 to 6.143; p&lt;0.05). The receiver operating characteristic curve revealed that the area under the curve for serum sASGR1 in predicting MASLD occurrence was 0.761 (95% CI 0.698 to 0.824), and its predictive performance increased to 0.863 (95% CI 0.813 to 0.913) when combined with AST and ALT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this group of patients with MASLD, sASGR1 levels are higher and are associated with the occurrence of MASLD, suggesting that sASGR1 may be an independent risk factor for MASLD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>The expression of organokines in serum and its relationship with inflammation, insulin resistance in obese patients, ChiCTR2200059056.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjdrc-2025-005638","type":"journal-article","created":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T15:30:17Z","timestamp":1769527817000},"page":"e005638","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Serum soluble ASGR1 concentration is elevated in patients with metabolic dysfunction-associated steatotic liver disease and is associated with adiponectin"],"prefix":"10.1136","volume":"14","author":[{"given":"Jing-Ming","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Metabolism and Endocrinology, First Affiliated Hospital of University of South China, Hengyang, Hunan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Yan","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Metabolism and Endocrinology, First Affiliated Hospital of University of South China, Hengyang, Hunan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Ting","family":"Deng","sequence":"additional","affiliation":[{"name":"Department of Metabolism and Endocrinology, First Affiliated Hospital of University of South China, Hengyang, Hunan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiao-Yang","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Metabolism and Endocrinology, First Affiliated Hospital of University of South China, Hengyang, Hunan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heng","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Metabolism and Endocrinology, First Affiliated Hospital of University of South China, Hengyang, Hunan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Ran","sequence":"additional","affiliation":[{"name":"Department of Metabolism and Endocrinology, First Affiliated Hospital of University of South China, Hengyang, Hunan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2706-4464","authenticated-orcid":false,"given":"Xinhua","family":"Xiao","sequence":"additional","affiliation":[{"name":"Department of Metabolism and Endocrinology, First Affiliated Hospital of University of South China, Hengyang, Hunan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,1,27]]},"reference":[{"key":"2026012707300637000_14.1.e005638.1","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000323"},{"key":"2026012707300637000_14.1.e005638.2","first-page":"1521","article-title":"Nonalcoholic fatty liver disease: a systematic review. JAMA. 2015 Jun 9;313(22):2263-73. doi: 10.1001\/jama.2015.5370","volume":"314","author":"Rinella","year":"2015","journal-title":"JAMA"},{"key":"2026012707300637000_14.1.e005638.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1503519"},{"key":"2026012707300637000_14.1.e005638.4","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","article-title":"The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis","volume":"7","author":"Riazi","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026012707300637000_14.1.e005638.5","doi-asserted-by":"publisher","DOI":"10.1161\/ATV.0000000000000153"},{"key":"2026012707300637000_14.1.e005638.6","doi-asserted-by":"crossref","first-page":"386","DOI":"10.21037\/hbsn-22-421","article-title":"An international Delphi consensus statement on metabolic dysfunction-associated fatty liver disease and risk of chronic kidney disease","volume":"12","author":"Sun","year":"2023","journal-title":"Hepatobiliary Surg Nutr"},{"key":"2026012707300637000_14.1.e005638.7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32511-3"},{"key":"2026012707300637000_14.1.e005638.8","doi-asserted-by":"publisher","DOI":"10.1097\/hep.0000000000000004"},{"key":"2026012707300637000_14.1.e005638.9","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2022.0365"},{"key":"2026012707300637000_14.1.e005638.10","doi-asserted-by":"crossref","first-page":"119","DOI":"10.21037\/hbsn-23-556","article-title":"The global burden of fatty liver disease: the major impact of China","volume":"13","author":"Lou","year":"2024","journal-title":"Hepatobiliary Surg Nutr"},{"key":"2026012707300637000_14.1.e005638.11","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.jhep.2021.05.003","article-title":"The Chinese Society of Hepatology position statement on the redefinition of fatty liver disease","volume":"75","author":"Nan","year":"2021","journal-title":"J Hepatol"},{"key":"2026012707300637000_14.1.e005638.12","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s12072-020-10094-2","article-title":"The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease","volume":"14","author":"Eslam","year":"2020","journal-title":"Hepatol Int"},{"key":"2026012707300637000_14.1.e005638.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.04.006"},{"key":"2026012707300637000_14.1.e005638.14","doi-asserted-by":"publisher","DOI":"10.1016\/s0304-4165(02)00318-5"},{"key":"2026012707300637000_14.1.e005638.15","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1161\/ATVBAHA.124.321076","article-title":"ASGR1 Deficiency Inhibits Atherosclerosis in Western Diet-Fed ApoE-\/- Mice by Regulating Lipoprotein Metabolism and Promoting Cholesterol Efflux","volume":"44","author":"Zhang","year":"2024","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2026012707300637000_14.1.e005638.16","doi-asserted-by":"crossref","first-page":"802","DOI":"10.4093\/dmj.2023.0124","article-title":"Deficiency of ASGR1 Alleviates Diet-Induced Systemic Insulin Resistance via Improved Hepatic Insulin Sensitivity","volume":"48","author":"Yu","year":"2024","journal-title":"Diabetes Metab J"},{"key":"2026012707300637000_14.1.e005638.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2022.121339"},{"key":"2026012707300637000_14.1.e005638.18","doi-asserted-by":"crossref","DOI":"10.1186\/s12944-024-02054-8","article-title":"The serum soluble ASGR1 concentration is elevated in patients with coronary artery disease and is associated with inflammatory markers","volume":"23","author":"Luo","year":"2024","journal-title":"Lipids Health Dis"},{"key":"2026012707300637000_14.1.e005638.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2010.05.018"},{"key":"2026012707300637000_14.1.e005638.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2012.10.029"},{"key":"2026012707300637000_14.1.e005638.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2011.12.025"},{"key":"2026012707300637000_14.1.e005638.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2011.05.003"},{"key":"2026012707300637000_14.1.e005638.23","doi-asserted-by":"crossref","first-page":"155329","DOI":"10.1016\/j.metabol.2022.155329","article-title":"Genome-wide association and Mendelian randomization study of fibroblast growth factor 21 reveals causal associations with hyperlipidemia and possibly NASH","volume":"137","author":"Larsson","year":"2022","journal-title":"Metab Clin Exp"},{"key":"2026012707300637000_14.1.e005638.24","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2362.2010.02338.x"},{"key":"2026012707300637000_14.1.e005638.25","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpha.2023.12.003","article-title":"New advances of adiponectin in regulating obesity and related metabolic syndromes","volume":"14","author":"Han","year":"2024","journal-title":"J Pharm Anal"},{"key":"2026012707300637000_14.1.e005638.26","doi-asserted-by":"crossref","DOI":"10.1016\/j.xcrm.2024.101884","article-title":"Associations between multiple metabolic biomarkers with steatotic liver disease subcategories: A 5-year Chinese cohort study","volume":"6","author":"Chen","year":"2025","journal-title":"Cell Rep Med"},{"key":"2026012707300637000_14.1.e005638.27","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.metabol.2010.09.003","article-title":"Serum total adiponectin in nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"60","author":"Polyzos","year":"2011","journal-title":"Metab Clin Exp"},{"key":"2026012707300637000_14.1.e005638.28","first-page":"418","article-title":"Guidelines for the prevention and treatment of metabolic dysfunction-associated (non-alcoholic) fatty liver disease (Version 2024)","volume":"32","year":"2024","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"key":"2026012707300637000_14.1.e005638.29","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2010.04.054"},{"key":"2026012707300637000_14.1.e005638.30","doi-asserted-by":"crossref","first-page":"25191","DOI":"10.1038\/s41598-024-76585-6","article-title":"Clinical significance of serum FGF21 levels in diagnosing nonalcoholic fatty liver disease early","volume":"14","author":"Xu","year":"2024","journal-title":"Sci Rep"},{"key":"2026012707300637000_14.1.e005638.31","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1210\/jc.2018-02414","article-title":"Plasma Fibroblast Growth Factor 21 Is Associated With Severity of Nonalcoholic Steatohepatitis in Patients With Obesity and Type 2 Diabetes","volume":"104","author":"Barb","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"2026012707300637000_14.1.e005638.32","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.07.044"},{"key":"2026012707300637000_14.1.e005638.33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2024.04.034"},{"key":"2026012707300637000_14.1.e005638.34","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/j.cmet.2025.04.014","article-title":"FGF21 reverses MASH through coordinated actions on the CNS and liver","volume":"37","author":"Rose","year":"2025","journal-title":"Cell Metab"},{"key":"2026012707300637000_14.1.e005638.35","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2009.06039.x"},{"key":"2026012707300637000_14.1.e005638.36","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M700484200"},{"key":"2026012707300637000_14.1.e005638.37","doi-asserted-by":"crossref","first-page":"683250","DOI":"10.3389\/fmed.2021.683250","article-title":"Adiponectin, Leptin, and IGF-1 Are Useful Diagnostic and Stratification Biomarkers of NAFLD","volume":"8","author":"Marques","year":"2021","journal-title":"Front Med"},{"key":"2026012707300637000_14.1.e005638.38","doi-asserted-by":"crossref","first-page":"5807","DOI":"10.1038\/s41467-020-19668-y","article-title":"Author Correction: AdipoR1\/AdipoR2 dual agonist recovers nonalcoholic steatohepatitis and related fibrosis via endoplasmic reticulum-mitochondria axis","volume":"12","author":"Xu","year":"2020","journal-title":"Nat Commun"},{"key":"2026012707300637000_14.1.e005638.39","doi-asserted-by":"crossref","first-page":"814","DOI":"10.3350\/cmh.2022.0099","article-title":"The usefulness of metabolic score for insulin resistance for the prediction of incident non-alcoholic fatty liver disease in Korean adults","volume":"28","author":"Lee","year":"2022","journal-title":"Clin Mol Hepatol"},{"key":"2026012707300637000_14.1.e005638.40","doi-asserted-by":"crossref","first-page":"1083032","DOI":"10.3389\/fendo.2023.1083032","article-title":"Prediction of MAFLD and NAFLD using different screening indexes: A cross-sectional study in U.S. adults","volume":"14","author":"Peng","year":"2023","journal-title":"Front Endocrinol"},{"key":"2026012707300637000_14.1.e005638.41","doi-asserted-by":"crossref","DOI":"10.1186\/s12944-023-01910-3","article-title":"Correlation between serum soluble ASGR1 concentration and low-density lipoprotein cholesterol levels: a cross-sectional study","volume":"22","author":"Luo","year":"2023","journal-title":"Lipids Health Dis"},{"key":"2026012707300637000_14.1.e005638.42","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/s41586-022-05006-3","article-title":"Inhibition of ASGR1 decreases lipid levels by promoting cholesterol excretion","volume":"608","author":"Wang","year":"2022","journal-title":"Nature New Biol"},{"key":"2026012707300637000_14.1.e005638.43","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.147038","article-title":"Hypomorphic ASGR1 modulates lipid homeostasis via INSIG1-mediated SREBP signaling suppression","volume":"6","author":"Xu","year":"2021","journal-title":"JCI Insight"},{"key":"2026012707300637000_14.1.e005638.44","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jhep.2018.08.026","article-title":"MicroRNA-378 promotes hepatic inflammation and fibrosis via modulation of the NF-\u03baB-TNF\u03b1 pathway","volume":"70","author":"Zhang","year":"2019","journal-title":"J Hepatol"},{"key":"2026012707300637000_14.1.e005638.45","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2017.38"},{"key":"2026012707300637000_14.1.e005638.46","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/ejcn.2013.1","article-title":"Factors determining the risk of the metabolic syndrome: is there a central role for adiponectin?","volume":"67","author":"Calton","year":"2013","journal-title":"Eur J Clin Nutr"},{"key":"2026012707300637000_14.1.e005638.47","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1038\/nature08991","article-title":"Adiponectin and AdipoR1 regulate PGC-1alpha and mitochondria by Ca(2+) and AMPK\/SIRT1","volume":"464","author":"Iwabu","year":"2010","journal-title":"Nature New Biol"},{"key":"2026012707300637000_14.1.e005638.48","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/cld.721","article-title":"The Association Between Nonalcoholic Fatty Liver Disease and Cardiovascular Disease Outcomes","volume":"12","author":"Wong","year":"2018","journal-title":"Clin Liver Dis (Hoboken)"}],"container-title":["BMJ Open Diabetes Research &amp; Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjdrc-2025-005638","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T15:30:21Z","timestamp":1769527821000},"score":1,"resource":{"primary":{"URL":"https:\/\/drc.bmj.com\/lookup\/doi\/10.1136\/bmjdrc-2025-005638"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,27]]},"published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1136\/bmjdrc-2025-005638"],"URL":"https:\/\/doi.org\/10.1136\/bmjdrc-2025-005638","relation":{},"ISSN":["2052-4897"],"issn-type":[{"value":"2052-4897","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]}}}